InvestorsHub Logo
Followers 32
Posts 2803
Boards Moderated 3
Alias Born 10/24/2015

Re: NY1972 post# 126

Tuesday, 04/26/2022 2:35:29 PM

Tuesday, April 26, 2022 2:35:29 PM

Post# of 386
Not that I'm aware. Some are planning trials without it. In 1H 2023, NKTX will file an IND amendment for NKX101 (an anti-NKG2DL CAR-NK). It will be tested in patients with HCC, intrahepatic cholangiocarcinoma, as well as surgically removed CRC where liver metastases remain. The cells will be delivered (no LD chemo before) by an injection into the hepatic artery, a standard technique for delivering certain anticancer agents to the liver and has been used for CAR-T cells in the past https://jitc.bmj.com/content/8/2/e001097.long

As for FATE, they plan on adding an ADR (alloimmune defence receptor, ALLO has assess to it as well)
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent FATE News